poisar

Stocks · News reference

HC Wainwright & Co. Maintains Buy on Unicycive Therapeutics, Lowers Price Target to $13

Benzinga Newsdesk
More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

UNCY
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. SEC EDGAR

    8-K filing — Unicycive Therapeutics, Inc. (UNCY)

    Filed: 2026-09-29 AccNo: 0001213900-26-104314 Size: 231 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

    UNCY
  2. Benzinga Newsdesk

    Unicycive Therapeutics Resubmits Its FDA New Drug Application For Oxylanthanum Carbonate For The Treatment Of Hyperphosphatemia In Patients With Chronic Kidney Disease On Dialysis; Expects PDUFA Date Six Months From Resubmission Date

    The Company anticipates United States Food and Drug Administration (FDA) acceptance of the NDA within 30 days and a new assigned PDUFA date to be six months from the date of resubmission.The NDA resubmission includes

    UNCY